Nivestim (Filgrastim)

Filgrastim, the active ingredient in Nivestim, is a granulocyte colony‑stimulating factor (G‑CSF) presented as a sterile solution for intravenous and subcutaneous use. It stimulates neutrophil production to reduce the duration of neutropenia in patients undergoing chemotherapy, stem‑cell transplantation, or exposed to radiation, and is used under medical supervision. GNH USA supplies Nivestim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality‑controlled shipments and regulatory compliance across EU and global markets.

Filgrastim is a granulocyte colony‑stimulating factor used to manage neutropenia associated with several clinical conditions.

Chemotherapy‑induced neutropenia: shortens the duration of severe neutropenia and helps maintain planned chemotherapy dosing. Neutropenia following bone marrow or peripheral blood stem cell transplantation: accelerates neutrophil recovery after transplant procedures. Severe chronic neutropenia: increases peripheral neutrophil counts to reduce infection risk in patients with congenital or acquired chronic neutropenia. Acute radiation syndrome: supports hematopoietic recovery after high‑dose radiation exposure.

Filgrastim may be associated with a range of adverse reactions, varying from mild to severe, that clinicians should monitor.

Common Side Effects: - Bone pain: deep aching pain in the long bones or back, often occurring within days of administration. - Headache: mild to moderate throbbing headache that may be transient or persist for several hours. - Injection site reactions: localized erythema, swelling, tenderness, or pruritus at the subcutaneous or intravenous injection site.

Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain and internal bleeding, requiring immediate medical attention. - Severe allergic reactions: anaphylaxis presenting with rash, bronchospasm, hypotension, or angioedema. - Capillary leak syndrome: rapid fluid shift leading to edema, hypotension, and possible organ dysfunction.

When using Filgrastim, several precautions should be observed to ensure safe and effective therapy. - Dose adjustment: assess renal and hepatic function and modify dosing in patients with significant impairment. - Monitoring: perform regular complete blood counts to track neutrophil response and detect excessive leukocytosis. - Allergy: discontinue immediately if signs of hypersensitivity such as rash, swelling, or respiratory distress appear. - Pregnancy and lactation: use only when the potential benefit justifies the potential risk to the fetus or infant. - Concomitant therapy: evaluate the need for caution when administered with other myeloid growth factors or cytotoxic agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Filgrastim can interact with other medicines, influencing efficacy or safety, and should be reviewed before co‑administration.

Major Interactions (Avoid): - Concurrent use with other granulocyte colony‑stimulating agents: may cause excessive neutrophil proliferation and increase risk of leukocytosis. - High‑dose chemotherapy regimens that cause profound myelosuppression: may exacerbate hematologic toxicity if not properly timed.

Moderate Interactions (Monitor Closely): - Corticosteroids: may blunt the neutrophil response to Filgrastim, requiring dose adjustment. - Antibiotics (e.g., quinolones): can mask signs of infection, complicating clinical assessment. - Live vaccines: immune response may be altered, reducing vaccine efficacy.